A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Response rate (complete and partial confirmed response)
研究概览
简要总结
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded to previous treatment. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth
详细描述
OBJECTIVES:
I. Determine the response rates (confirmed, complete, and partial) in patients with platinum- and taxane-refractory stage III or IV ovarian epithelial or primary peritoneal cancer treated with imatinib mesylate.
II. Determine the toxicity of this drug in these patients. III. Correlate, preliminarily, CD117 and platelet-derived growth factor receptor expression levels with response in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed epithelial carcinoma of the ovary or primary peritoneal serous papillary carcinoma
- •No mixed Mullerian tumors
- •No borderline ovarian tumors
- •Stage III or IV disease at time of diagnosis by surgical staging
- •Expression of KIT (CD117) and/or platelet-derived growth factor receptor by immunohistochemistry
- •Relapsed within 6 months after completion of or progressed while receiving prior frontline chemotherapy with a platinum (cisplatin or carboplatin) and a taxane(paclitaxel or docetaxel) administered concurrently or sequentially
- •Measurable disease
- •Performance status - Zubrod 0-1
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Hemoglobin at least 9 g/dL (transfusion allowed)
- •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- •SGOT or SGPT no greater than 2.5 times ULN
- •Creatinine no greater than 1.5 times ULN
- •No New York Heart Association class III or IV heart disease (e.g., congestive heart failure or myocardial infarction within the past 2 months)
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective barrier contraception during and for 3 months after study participation
- •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission
- •At least 28 days since prior biologic therapy
- •No concurrent anticancer biologic therapy
- •No concurrent cytokines (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])
- •At least 28 days since prior chemotherapy
- •No more than 3 prior chemotherapy regimens in addition to frontline chemotherapy
- •Retreatment with a platinum agent or with the same taxane as in the frontline regimen is not counted as an additional regimen
- •No concurrent chemotherapy
- •Prior hormonal therapy allowed
- •Recovered from prior radiotherapy
- •No prior radiotherapy to more than 25% of bone marrow
- •No concurrent radiotherapy
- •Prior surgical debulking allowed for relapsed disease if measurable disease remains after surgery
- •At least 14 days since prior major surgery
- •Recovered from all prior surgery
- •At least 28 days since prior investigational drugs
- •No concurrent therapeutic doses of warfarin for anticoagulation (heparin or mini-dose warfarin (1 mg/day) allowed)
- •No other concurrent anticancer agents
- •No other concurrent investigational drugs
排除标准
- 未提供
研究组 & 干预措施
Treatment (imatinib mesylate)
Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
干预措施: imatinib mesylate (Drug)
Treatment (imatinib mesylate)
Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Response rate (complete and partial confirmed response)
时间窗: Up to 3 years
次要结局
- Toxicity as assessed by NCI Common Toxicity Criteria version 2.0(Up to 3 years)